MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Portfolio Companies: Montreux Equity
Pulmonx Corporation (NASDAQ: LUNG)
Organization & Developments: Pulmonx
Parents
Pulmonx Corporation (NASDAQ: LUNG)
Children
*Its Chartis System measures air flow and pressure readings in various areas of the lungs to determine which emphysema patients are most likely to benefit from the Zephyr Endobronchial Valve.
*Minimally invasive therapeutic products for emphysema
*PulmonX is combating the symptoms of emphysema—breathlessness and fatigue—with its Zephyr Endobronchial Valve.
*The company has also developed diagnostic tools to aid in this therapy.
*The one-way valve is placed in parts of the patient’s lungs to block air flow into diseased areas of the lungs.
*This is intended to make the lungs operate more efficiently with healthy tissue while also allowing trapped air and secretions to be removed from the problematic areas.
*ZEPHYR ENDOBRONCHIAL VALVE SYSTEM
2022: Pulmonx Corp (LUNG) Investor Presentation - Slideshow_ seekingalpha.com
2022: Pulmonx: An Ideal Takeout Candidate_ seekingalpha.com
2023: The Prognosis For Pulmonx Corporation (NASDAQ:LUNG)
2024: Pulmonx Corporation 2023 Q4 - Results - Earnings Call Presentation
2024: Pulmonx: Low Bar For Q2 Earnings
2024: Pulmonx: Revisiting Thesis Following Management Change
Jumps
*Key People: Pulmonx
Finance & Acquisitions: Pulmonx